Iron-chelation therapy with oral chelators in patients with thalassemia major

References

• Wintrobe MM, Greer JP. Wintrobe's clinical hematology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. pp. 1099–100.
   Google Scholar
• Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1–9.
   PubMed Web of Science ®Google Scholar
• Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet. 2006;9:124–6.
   PubMedGoogle Scholar
• Neufeld EJ. Update on iron chelators in thalassemia. Hematol Am Soc Hematol Educ Program 2010;2010:451–5.
   PubMedGoogle Scholar
• Cianciulli P. Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis. 2009;1:e2009034.
   PubMedGoogle Scholar
• Chua-anusorn W, Macey DJ, Webb J, de la Motte , Hall P, St Pierre TG. Effects of prolonged iron loading in the rat using both parenteral and dietary routes. Biometals 1999;12:103–13.
   PubMed Web of Science ®Google Scholar
• Fischer R, Tiemann CD, Engelhardt R, Nielsen P, Durken M, Gabbe EE, et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol. 1999;60:289–99.
   PubMed Web of Science ®Google Scholar
• Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, et al. Pharmacokinetics of deferiprone in patients with beta-thalassaemia: impact of splenectomy and iron status. Clin Pharmacokinet. 2011;50:41–50.
   PubMed Web of Science ®Google Scholar
• Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3:795–805.
   PubMedGoogle Scholar
• Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1–15.
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873–80.
   PubMed Web of Science ®Google Scholar
• Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196–208.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295–300.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557–66.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:884–93.
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403–9.
   PubMed Web of Science ®Google Scholar
• Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752–9.
   PubMed Web of Science ®Google Scholar
• Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, et al. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Ann Hematol. 2012;91(9):1443–9.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin 2011;35:186–98.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012;119:2746–53.
   PubMed Web of Science ®Google Scholar
• Meerpohl JJ, Antes G, Rucker G, Fleeman N, Motschall E, Niemeyer CM, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2012;2:CD007476.
   PubMedGoogle Scholar
• Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583–7.
   PubMed Web of Science ®Google Scholar
• Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36:2523–38.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf. 2007;6:235–9.
   PubMed Web of Science ®Google Scholar
• Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos. 1992;20:256–61.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108:305–12.
   PubMed Web of Science ®Google Scholar
• Piperno A. Classification and diagnosis of iron overload. Haematologica 1998;83:447–55.
   PubMed Web of Science ®Google Scholar